Working... Menu

Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00352417
Recruitment Status : Completed
First Posted : July 14, 2006
Results First Posted : July 20, 2012
Last Update Posted : July 27, 2012
Information provided by (Responsible Party):
Tallikut Pharmaceuticals, Inc.

Brief Summary:
This is a study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with carotid stenosis scheduled for elective carotid endarterectomy

Condition or disease Intervention/treatment Phase
Atherosclerosis Drug: VIA-2291 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Effects of VIA-2291, a 5-Lipoxygenase Inhibitor, on Atherosclerotic Plaque and Biomarkers of Vascular Inflammation in Patients With Carotid Stenosis Undergoing Elective Carotid Endarterectomy
Study Start Date : July 2006
Actual Primary Completion Date : July 2008
Actual Study Completion Date : July 2008

Arm Intervention/treatment
Experimental: VIA-2291 Drug: VIA-2291
100 mg, oral dosing, 1 time daily for 12 weeks
Other Name: atreleuton

Placebo Comparator: Placebo
Matching Placebo
Drug: Placebo
oral dosing, 1 time daily for 12 weeks

Primary Outcome Measures :
  1. Percent Cross-sectional Area of Macrophages in Plaque Tissue [ Time Frame: 12 weeks ]
    Effect of VIA-2291 100-mg relative to placebo after 12 weeks of daily dosing on the percent cross-sectional area of macrophages in plaque tissue using an anti-CD68 antibody

Secondary Outcome Measures :
  1. Percent Cross-sectional Area of Anti-5-Lipoxygenase Staining in Plaque Tissue [ Time Frame: 12 weeks ]
    Effect of VIA-2291 100-mg relative to placebo after 12 weeks of daily dosing on the percent cross-sectional area of anti-5-Lipoxygenase staining in plaque tissue

  2. Change From Baseline in Whole Blood Leukotriene B4 Production [ Time Frame: Baseline and 12 weeks ]
  3. Change From Baseline in Urine Leukotriene E4 Adjusted for Creatinine [ Time Frame: Baseline and 12 Weeks ]
  4. Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) [ Time Frame: Baseline and 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female patients must be of non-childbearing potential
  • Carotid stenosis between 60% and 90% and to be scheduled for CEA surgery
  • One or more of the following clinical features: Prior history >4 weeks of cerebrovascular accident (CVA) or transient ischemic attack (TIA) consistent with North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria or prior history of amaurosis fugax occurring at any time
  • Diabetes haemoglobin (Hb) A1c between 7.0 and 11% or a history of two or more fasting blood glucose levels >6.9 mmol/L
  • Baseline hsCRP >2 mg/L
  • Echolucent plaque

Exclusion Criteria:

  • Acute CVA or TIA within 4 weeks of enrollment or the presence of ulcerated or unstable plaque requiring urgent carotid endarterectomy
  • Renal insufficiency defined as creatinine >1.5 x upper limit of normal (ULN)
  • Cirrhosis, recent hepatitis, alanine aminotransferase (ALT) >1 x ULN (i.e., above the normal range) or positive screening test for hepatitis B (hepatitis B surface antigen) or hepatitis C (by ELISA)
  • Uncontrolled diabetes mellitus within 1 month prior to study screening, defined as HbA1c >11% at screening
  • Congestive heart failure (CHF) defined by the New York Heart Association as functional Class III or IV
  • Recent acute coronary syndrome event or coronary artery bypass graft (CABG) surgery (within 4 weeks of enrollment)
  • Current atrial fibrillation
  • Planned cardiac intervention
  • Acetaminophen use in any form in the 7 days before enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00352417

Layout table for location information
Azienda Ospedali Riuniti Ancona
Ancona, Italy
Presidio Ospedaliero SS Filippo e Nicola
Avezzano, Italy
Centro Studi Sull'Invecchiamento
Chieti Scalo, Italy
Sponsors and Collaborators
Tallikut Pharmaceuticals, Inc.
Layout table for investigator information
Study Director: Rebecca Taub, MD VIA Pharmaceuticals

Layout table for additonal information
Responsible Party: Tallikut Pharmaceuticals, Inc. Identifier: NCT00352417     History of Changes
Other Study ID Numbers: VIA-2291-02
2006-001635-21 ( EudraCT Number )
First Posted: July 14, 2006    Key Record Dates
Results First Posted: July 20, 2012
Last Update Posted: July 27, 2012
Last Verified: July 2012

Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Lipoxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antisickling Agents
Nucleic Acid Synthesis Inhibitors